3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
108
Ovarian Neoplasms
64
Neoplasms
61
Fallopian Tube Neoplasms
40
Lung Neoplasms
37
Breast Neoplasms
33
Neoplasm Metastasis
25
Carcinoma, Ovarian Epithelial
25
Triple Negative Breast Neoplasms
21
Small Cell Lung Carcinoma
20
Esophageal Neoplasms
19
Endometrial Neoplasms
19
Colorectal Neoplasms
15
Advanced Solid Tumors
14
Squamous Cell Carcinoma of Head and Neck
13
Lymphoma, Large B-Cell, Diffuse
13
Unspecified Adult Solid Tumor, Protocol Specific
12
Stomach Neoplasms
11
Melanoma
11
Central Nervous System Neoplasms
11
Uterine Cervical Neoplasms
10
Pancreatic Neoplasms
10
Astrocytoma
10
Neuroblastoma
9
Medulloblastoma
9
Head and Neck Neoplasms
9
Carcinoma
9
Urinary Bladder Neoplasms
8
Solid Tumors
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Interventions
pembrolizumab
1
bemarituzumab
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Squamous-Cell Non-Small-Cell Lung Cancer
×
Carboplatin
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts